Search

Displaying results 3441 - 3450 of 7503 in total
  1. Drug

    Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15788
    ApprovedInvestigationalWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  2. Drug

    Olaratumab

    go.drugbank.com/drugs/DB06043
    ApprovedInvestigational

    Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.

  3. Drug

    Amcipatricin

    go.drugbank.com/drugs/DB12333
    Investigational

    Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment … SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone

  4. Drug

    Gluconic Acid

    go.drugbank.com/drugs/DB13180
    ApprovedInvestigational

    Gluconic acid or gluconate is used to maintain the cation-anion balance on electrolyte solutions.

  5. Drug

    Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

    go.drugbank.com/drugs/DB16443
    Investigational

    The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. … It also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2[A226853].

  6. Drug

    Benoxaprofen

    go.drugbank.com/drugs/DB04812
    ApprovedWithdrawn

    The holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982.

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal
  7. Drug

    Rauwolfia serpentina root

    go.drugbank.com/drugs/DB09363
    Investigational

    This product was approved prior to Jan 1, 1982, but since, has been discontinued due to its propensity for leading to depression [L1616, L1630]. … Rauwolfia serpentina is also commonly referred to as _Sarpaghanda_ [A32097].

  8. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  9. Drug

    Silicon dioxide

    go.drugbank.com/drugs/DB11132
    Approved

    Inhalation of fine crystals is toxic to humans leading to respiratory toxicity. In powdered food products and pharmaceutical tablets, silicon dioxide is added as a flow agent to absorb water.

    Mixtures: Alegria Neo
  10. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757] … CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.